A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Carcinoma Non-small-cell Lung
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Sponsor, excluding supply chain management personnel and unblinded monitors of site pharmacies, will remain blinded.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 130 years
- Gender
- Both males and females
Description
Approximately 360 patients will be randomized in a 2:1 to receive treatment with durvalumab or placebo therapy. The primary objective of this study is to assess the efficacy of durvalumab treatment compared with placebo in terms of PFS
Approximately 360 patients will be randomized in a 2:1 to receive treatment with durvalumab or placebo therapy. The primary objective of this study is to assess the efficacy of durvalumab treatment compared with placebo in terms of PFS
Tracking Information
- NCT #
- NCT03706690
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Yilong Wu, MD Guangdong General Hospital, Guangdong Lung Cancer Institute
Get Well Soon